Wikisage, the free encyclopedia of the second generation, is digital heritage

Perampanel: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
m (wLink)
(2 intermediate revisions by the same user not shown)
Line 5: Line 5:


<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf</ref>
<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf</ref>
Perampanel was efficacious and well tolerated, despite the observation that the patient population exhibited characteristics of highly refractory epilepsy
Perampanel was efficacious and well tolerated, despite the observation that the patient population exhibited characteristics of highly refractory [[epilepsy]]


<ref>http://n.neurology.org/content/suppl/2016/04/10/WNL.0000000000001930.DC3/french_950.pdf</ref>
<ref>http://n.neurology.org/content/suppl/2016/04/10/WNL.0000000000001930.DC3/french_950.pdf</ref>
Line 13: Line 13:


[http://onlinelibrary.wiley.com/doi/10.1111/epi.12212/full Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies]
[http://onlinelibrary.wiley.com/doi/10.1111/epi.12212/full Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies]
{{wikidata|Q868658}}
<references/>
<references/>
[[Category:Anticonvulsant]]
[[Category:Anticonvulsant]]

Revision as of 19:24, 10 January 2018